Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

Felix Keil, Antonia Maria Susanne Müller, Andrea Berghold, Veronika Buxhofer-Ausch, Judith Schuster, Regina Riedl, Corinne Vorburger, Alexandra Boehm, Michael Panny, Thomas Noesslinger, Richard Greil, Panagiotis Samaras, Thomas Pabst

Blood (2022) 140 (Supplement 1): 1180–1182.

https://doi.org/10.1182/blood-2022-157917

Published: 2022

Journal Articles

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

Blood (2018) 132 (18): 1936–1950.

https://doi.org/10.1182/blood-2018-02-833582

Published: 2018

Includes: Supplemental data

Journal Articles

Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis

Niklas Mueller, MD, Daniel Wicklein, PhD, Gregor Eisenwort, MD PhD, Juliana Schwaab, MD, Mohamad Jawhar, MD, Alexandra Boehm, MD, Harald Herrmann, MD, Gabriele Stefanzl, Gregor Hoermann, Wolfgang R. Sperr, MD, Michel Arock, PharmD,PhD, Andreas Reiter, MD, Udo Schumacher, MD, Peter Valent, MD

Blood (2016) 128 (22): 1955.

https://doi.org/10.1182/blood.V128.22.1955.1955

Published: 2016

Journal Articles

Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis

Blood (2013) 122 (21): 2145.

https://doi.org/10.1182/blood.V122.21.2145.2145

Published: 2013

Journal Articles

Clofarabine/Cyclophosphamide (ClofCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Werner Rabitsch, M.D., Alexandra Boehm, MD, Peter Schellongowski, MD, Peter Kalhs, MD, Peter Valent, MD, Wolfgang R Sperr, MD

Blood (2012) 120 (21): 4504.

https://doi.org/10.1182/blood.V120.21.4504.4504

Published: 2012

Journal Articles

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

Michael Kneidinger, MD, Karoline V. Gleixner, md, Rudin Kondo, md, Puchit Samorapoompichit, md, Anja Vales, md, Maria T. Krauth, md, Matthias Mayerhofer, md, Alexander Gruze, Winfried F. Pickl, md, Khaled Greish, Alexandra Boehm, md, Wolfgang R. Sperr, md, Hiroshi Maeda, md, phd, Peter Valent, md

Blood (2006) 108 (11): 1901.

https://doi.org/10.1182/blood.V108.11.1901.1901

Published: 2006

Journal Articles

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Michael Kneidinger, MD, Peter Valent, MD, Karoline V. Gleixner, MD, Stefan Florian, MD, Alexandra Boehm, MD, Karoline Sonneck, MD, Margit Weghofer, Christian Lupinek, Susanne Vrtala, MD, Anja Vales, MD, Rudolf Valenta, MD, Giulio Superti-Furga, PhD, Francis Y. Lee, PhD

Blood (2006) 108 (11): 1365.

https://doi.org/10.1182/blood.V108.11.1365.1365

Published: 2006

Journal Articles

Prognostic Significance of Serial Determinations of LDH Levels in Primary ( De Novo ) Myelodysplastic Syndromes.

Friedrich Wimazal, MD, Wolfgang R. Sperr, MD, Anja Vales, MD, Michael Kundi, MD, Alexandra Boehm, MD, Renate Thalhammer, MD, Ilse Schwarzinger, MD, Peter Valent, MD

Blood (2006) 108 (11): 4828.

https://doi.org/10.1182/blood.V108.11.4828.4828

Published: 2006

Journal Articles

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Karoline Sonneck, MD, Alexandra Boehm, MD, Puchit Samorapoompichit, MD, Alexander Gruze, Winfried Pickl, Paul Manley, Doriano Fabbro, Christian Sillaber, Peter Valent

Blood (2005) 106 (11): 3523.

https://doi.org/10.1182/blood.V106.11.3523.3523

Published: 2005

Journal Articles

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

Alexandra Boehm, MD, Stefan Florian, MD, Karoline Gleixner, Karoline Sonneck, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Peter Valent, MD, Wolfgang R. Sperr, MD

Blood (2005) 106 (11): 3518.

https://doi.org/10.1182/blood.V106.11.3518.3518

Published: 2005

Journal Articles

In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.

Matthias Mayerhofer, MD, Alexandra Boehm, MD, Karl J. Aichberger, MD, Harald Esterbauer, MD, PhD, Sophia Derdak, MD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2005) 106 (11): 4834.

https://doi.org/10.1182/blood.V106.11.4834.4834

Published: 2005

Journal Articles

Clinical Course and Prognosis in Mast Cell Proliferative Disorders: A 17 Year Experience in a Single Center.

Wolfgang R. Sperr, MD, Friedrich Wimazal, MD, Alexandra Boehm, MD, Alexander W. Hauswirth, MD, Stefan Florian, Robert Fritsche-Polanz, MD, Manuela Foedinger, MD, Peter Valent, MD

Blood (2004) 104 (11): 4741.

https://doi.org/10.1182/blood.V104.11.4741.4741

Published: 2004

Journal Articles

Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.

Alexandra Boehm, MD, Karl J. Aichberger, MD, Matthias Mayerhofer, MD, Maria-Theresa Krauth, MD, Sophia Derdak, PhD, Winfried F. Pickl, MD, Puchit Samorapoompichit, MD, Christian Sillaber, MD, Stefan Florian, Karoline Sonneck, MD, Wolfgang R. Sperr, MD, Peter Valent, MD

Blood (2004) 104 (11): 2544.

https://doi.org/10.1182/blood.V104.11.2544.2544

Published: 2004

NARROW

A Randomized Phase II Trial Comparing BeEAM with BEAM As Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma Patients

CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis

Identification of CD44 As a RAS-MEK-Regulated Invasion Receptor That Is Overexpressed in Neoplastic Mast Cells and Triggers Disease Expansion in Advanced Systemic Mastocytosis

Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis

Clofarabine/Cyclophosphamide (ClofCy) for Debulking refractory Acute Leukemias Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Prognostic Significance of Serial Determinations of LDH Levels in Primary ( De Novo ) Myelodysplastic Syndromes.

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Inhibition of Growth of Neoplastic Mast Cells by CD44 mAb A3D8 Is Associated with G1 Cell Cycle Arrest and Apoptosis.

In Vitro and In Vivo Antileukemic Effects of the mTOR-Targeting Drug Rapamycin in Patients with Imatinib-Resistant CML.

Clinical Course and Prognosis in Mast Cell Proliferative Disorders: A 17 Year Experience in a Single Center.

Targeting of mTOR in AML Is Associated with Decreased Growth of Leukemic Cells and Downregulation of VEGF.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only